2seventy bio, Inc. (TSVT)

NASDAQ: TSVT · IEX Real-Time Price · USD
14.40
-0.53 (-3.55%)
At close: Dec 7, 2022 4:00 PM
15.00
+0.60 (4.17%)
After-hours: Dec 7, 2022 6:00 PM EST
-3.55%
Market Cap 566.10M
Revenue (ttm) 51.36M
Net Income (ttm) -291.98M
Shares Out 38.57M
EPS (ttm) -11.94
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 386,393
Open 14.64
Previous Close 14.93
Day's Range 14.37 - 15.04
52-Week Range 9.91 - 34.02
Beta n/a
Analysts Buy
Price Target 30.77 (+113.7%)
Earnings Date Dec 7, 2022

About TSVT

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. [Read more]

Industry Biotechnology
Founded 2021
Employees 437
Stock Exchange NASDAQ
Ticker Symbol TSVT
Full Company Profile

Financial Performance

In 2021, 2seventy bio's revenue was $54.52 million, a decrease of -78.03% compared to the previous year's $248.12 million. Losses were -$292.21 million, 143.3% more than in 2020.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for TSVT stock is "Buy." The 12-month stock price forecast is 30.77, which is an increase of 113.68% from the latest price.

Price Target
$30.77
(113.68% upside)
Analyst Consensus: Buy
Stock Forecasts

News

2seventy bio, Inc. (TSVT) Reports Q3 Loss, Tops Revenue Estimates

2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of -1.15% and 25.71%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Does 2seventy bio, Inc. (TSVT) Have the Potential to Rally 97% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 96.9% in 2seventy bio, Inc. (TSVT). While the effectiveness of this highly sought-after metric is questionable, t...

1 month ago - Zacks Investment Research

2seventy bio Announces Plans to Initiate KarMMa-9 Study of Abecma (idecabtagene vicleucel) in Newly Diagnosed Multipl...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) today announced plans to initiate the KarMMa-9 study to evaluate Abecma (idecabtagene vicleucel) in newly diagnosed multiple myeloma ...

3 months ago - Business Wire

2seventy bio to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that members of the management team will participate in the followin...

3 months ago - Business Wire

2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the second quarter ended ...

3 months ago - Business Wire

The 5 Top Profit & Protection Stocks to Buy for 2022

It's important to know which quantitative factors make a stock worthwhile. These five have the attributes needed for success.

Other symbols: SHLSBJREALW
5 months ago - InvestorPlace

2seventy bio to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho P...

6 months ago - Business Wire

2seventy bio Reports First Quarter Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the first quarter ended M...

6 months ago - Business Wire

2seventy bio Presents New Preclinical Data on bbT369, an Investigational Dual-Targeting Gene-Edited CAR T Cell Therap...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, will present preclinical data on bbT369, an investigational novel CD79a/CD20 dual-ta...

7 months ago - Business Wire

2seventy bio to Participate in CG Horizons in Oncology Virtual Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the CG Horizons in Oncology Virtual Conference, on the Attacking AML: New Approaches Panel on...

8 months ago - Business Wire

2seventy bio Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, today reported financial results and recent highlights for the fourth quarte...

8 months ago - Business Wire

2seventy bio Secures $170 Million in Private Placement Equity Financing

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), a leading immuno-oncology cell therapy company, announced today that it has agreed to sell approximately 13,934,427 shares o...

8 months ago - Business Wire

2seventy bio Announces Key Management Appointments

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (NASDAQ: TSVT) announced that Steven Bernstein, M.D. will join the company effective today and assume the role of chief medical officer (CMO...

9 months ago - Business Wire

2seventy bio to Participate in Upcoming Healthcare Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will present at the following upcoming investor conferences: SVB Leerink 10th Annual Global Healthcar...

9 months ago - Business Wire

2seventy bio Shares Key Milestones and Business Updates for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #TSVT--2seventy bio, Inc. (Nasdaq: TSVT), an emerging immuno-oncology cell therapy company, today provided an update on the company's outlook for 2022. “It has been a...

10 months ago - Business Wire

2seventy bio Announces Expanded Collaboration Agreement With Novo Nordisk to Continue Development of in vivo Gene Edi...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ:TSVT) today announced that it has entered into an option and license agreement with Novo Nordisk for joint research and development of an in...

11 months ago - Business Wire

2seventy bio Presents Data Across Multiple Cell Therapy Programs at ASH 2021 Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) today announced data from its broad oncology cell therapy portfolio, including updated results from the CRB-402 study of bb21217 and ...

11 months ago - Business Wire

2seventy bio to Present at the 5th Annual Cowen IO Next Summit

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (Nasdaq: TSVT) announced today that it will participate in a fireside chat at the 5th Annual Cowen IO Next Summit on November 15, at 1:15pm ET. A we...

1 year ago - Business Wire

2seventy bio to Present Data from its Portfolio of Oncology Cell Therapies at the 63rd American Society of Hematology...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc. (NASDAQ: TSVT) announced today that data from its pipeline of oncology cell therapies will be presented, including two oral presentations, at the 63...

1 year ago - Business Wire

2seventy bio Completes Spin Transaction and Launches Innovative Immuno-oncology Cell Therapy Company

CAMBRIDGE, Mass.--(BUSINESS WIRE)--2seventy bio, Inc., (NASDAQ: TSVT), an emerging immuno-oncology company today announced its official launch as an independent, publicly traded company. 2seventy bio wi...

1 year ago - Business Wire